U.S. District Judge Roy Altman ruled that the drugmaker Eli Lilly And Co (NYSE:LLY) cannot rely on state law to stop a compounding pharmacy, RXCompoundStore.com, from marketing its version of the drug tirzepatide.  Eli Lilly markets tirzepatide as Mounjaro for diabetes and Zepbound for weightloss. According to Judge Altman, Lilly’s attempt to prevent this through the courts was seen as an effort to circumvent federal law. “We think Eli Lilly is using state law to enforce the terms of the FDCA [Federal Food, Drug, and Cosmetic Act], which … is a task generally ‘reserve[d] to the FDA,'” Altman wrote, adding that the court will not allow Lilly “to use state law as a back door to ...